Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

GenVec signs new agreement with Novartis for supply of services relating to development materials

GenVec, Inc. today announced a new agreement for the supply of services relating to development materials with Novartis, related to the companies' collaboration in hearing loss and balance disorders. Under this new agreement, GenVec could receive approximately $13 million over four years to manufacture clinical trial material for up to two lead candidates.

7 Aug 2010

Research Roundups: Expanding Medicaid; More spending doesn't reduce mortality; Colonoscopy cost effectiveness; Kids, asthma and access to care

Health Affairs: Little Evidence Of Correlation Between Growth In Health Care Spending And Reduced Mortality - This study examines differences in hospital mortality and cost between 2000 and 2004 for patients at 122 U.S. hospitals, with seven common medical diagnoses: acute myocardial infarction, chronic obstructive pulmonary disease, community-acquired pneumonia, congestive heart failure, cerebrovascular accident (also called ischemic stroke), sepsis, or urinary tract infection.

7 Aug 2010

Need for trained medical professionals to treat medical emergencies in high school athletes

As summer football practice gets into full swing, it's essential to be aware of the risk of exertional heat stroke (EHS) in high school athletes, according to a Safety Alert in The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

6 Aug 2010

GenVec reports net loss of $4.2M for second-quarter 2010

GenVec, Inc. today announced its financial results for the second quarter ended June 30, 2010.

6 Aug 2010

Akonni Biosystems receives patent for TruTip Extraction Kits

Akonni Biosystems, a developer of low-cost, multiplex molecular diagnostic testing systems, today announced that the United States Patent and Trademark Office issued a patent on July 20, 2010 for its method for rapidly purifying nucleic acids. U.S. Patent No. 7,759,112 entitled, "Apparatus, system, and method for purifying nucleic acids" protects the Company's use of its pioneering nucleic acid binding matrix when inserted into a pipette tip, tubing or cartridge for nucleic acid purification. The patent is owned by Akonni Biosystems.

6 Aug 2010

BioCryst second-quarter total revenues increase to $7.6 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

CEL-SCI produces and fills first lot of Multikine

CEL-SCI Corporation announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer.

5 Aug 2010

Americans stop seeking medical care for recent illness, survey reveals

With unemployment rates remaining at an all-time high, one in five Americans chose not to seek medical care for a recent illness or injury, with four out of 10 citing cost as the primary factor, according to a Deloitte Center for Health Solutions survey of more than 4,000 adults in the United States.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

NanoBio Corporation receives U.S. patent for nanoemulsion technology

NanoBio Corporation announced today that it has been awarded a seventh U.S. patent covering its novel nanoemulsion technology. The new claims encompass methods of treating Herpes Simplex I infections, including herpes labialis (commonly referred to as cold sores), using NanoBio's proprietary anti-infective nanoemulsion product candidates.

5 Aug 2010

Foldit players to focus on designing novel proteins

Computer scientists and biochemists at the University of Washington two years ago launched an ambitious project harnessing the brainpower of computer gamers to solve medical problems. The game, Foldit, turns one of the hardest problems in molecular biology into a game a bit reminiscent of Tetris. Thousands of people have now played a game that asks them to fold a protein rather than stack colored blocks or rescue a princess.

5 Aug 2010

Scientist invents new approach to boost body's response to vaccinations

As the medical community searches for better vaccines and ways to deliver them, a University of Rochester scientist believes he has discovered a new approach to boosting the body's response to vaccinations.Richard P. Phipps, Ph.D., found that the same molecules used in drugs that treat diabetes also stimulate B cells in the immune system, pushing them to make antibodies for protection against invading microorganisms.

5 Aug 2010

Review affirms hand therapy as one of most vital treatment steps in recovery from hand injury surgery

Hand therapy is one of the most vital treatment steps in recovery from hand injury surgery, according to a literature review published in the August 2010 issue of The Journal of the American Academy of Orthopaedic Surgeons. In fact, many patients spend more time with the hand therapist than the orthopaedic surgeon in the effort to ensure the best results and long-term recovery.

4 Aug 2010

PCV-7 vaccine introduction leads to changing patterns of hemolytic uremic syndrome

Introduction of the PCV-7 vaccine to prevent invasive pneumococcal disease (IPD) has led to a shift in the types of bacteria causing hemolytic uremic syndrome (HUS)—an important cause of acute kidney failure in children, reports a study in the August issue of The Pediatric Infectious Disease Journal.

4 Aug 2010

Matrixx Initiatives first-quarter net loss reduces to $2.4 million

Matrixx Initiatives, Inc., an over-the-counter healthcare company that develops and markets Zicam® products, today announced financial results for its fiscal first quarter ended June 30, 2010.

4 Aug 2010

Victory Pharma acquires assets of MiddleBrook Pharmaceuticals

Victory Pharma, Inc. today announced that it has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc..

4 Aug 2010

ICU Medical's Neutron Neutral-Pressure Needleless Connector receives FDA clearance

ICU Medical, Inc., a worldwide leader in the development, manufacture and sale of proprietary, disposable medical connection systems for use in vascular therapy applications, today confirmed that it has received FDA 510-k clearance for the Neutron™ Neutral-Pressure Needleless Connector.

4 Aug 2010

Vical second-quarter revenues decrease to $2.1 million

Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.

3 Aug 2010